Immutep Says Phase 2B Trial of Head, Neck Cancer Combination Therapy Shows 'Strong' Overall Survival; Shares Up 3%

MT Newswires Live

Dec 12, 2024

Immutep (ASX:IMM) said its phase 2b trial evaluating eftilagimod alpha in combination with Keytruda for patients with head and neck squamous cell cancer showed "strong" overall survival, progression-free survival, and durability, according to a Thursday filing with the Australian bourse.

The 12-month overall survival rate was 67%, well above historical controls, while the interim median duration of response was 9.3 months, the filing said. The median overall survival has not yet been reached.

The Tacti-003 study also found the combination therapy continues to be well-tolerated, with no new safety concerns identified, the filing said.

The biotechnology company's shares rose nearly 3% in afternoon trade Thursday.

Price (AUD): $0.37, Change: $+0.01, Percent Change: +2.82%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2490828377"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2490828377\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2490828377?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-12 11:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490828377","market":"hk","top_or_hot":-1,"title":"Immutep Says Phase 2B Trial of Head, Neck Cancer Combination Therapy Shows 'Strong' Overall Survival; Shares Up 3%","media":"MT Newswires Live","content":"<html><body><p> Immutep (ASX:IMM) said its phase 2b trial evaluating eftilagimod alpha in combination with Keytruda for patients with head and neck squamous cell cancer showed \"strong\" overall survival, progression-free survival, and durability, according to a Thursday filing with the Australian bourse.</p><p>The 12-month overall survival rate was 67%, well above historical controls, while the interim median duration of response was 9.3 months, the filing said. The median overall survival has not yet been reached.</p><p>The Tacti-003 study also found the combination therapy continues to be well-tolerated, with no new safety concerns identified, the filing said.</p><p>The biotechnology company's shares rose nearly 3% in afternoon trade Thursday.</p><p>Price (AUD): $0.37, Change: $+0.01, Percent Change: +2.82%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep Says Phase 2B Trial of Head, Neck Cancer Combination Therapy Shows 'Strong' Overall Survival; Shares Up 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep Says Phase 2B Trial of Head, Neck Cancer Combination Therapy Shows 'Strong' Overall Survival; Shares Up 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-12 11:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Immutep (ASX:IMM) said its phase 2b trial evaluating eftilagimod alpha in combination with Keytruda for patients with head and neck squamous cell cancer showed \"strong\" overall survival, progression-free survival, and durability, according to a Thursday filing with the Australian bourse.</p><p>The 12-month overall survival rate was 67%, well above historical controls, while the interim median duration of response was 9.3 months, the filing said. The median overall survival has not yet been reached.</p><p>The Tacti-003 study also found the combination therapy continues to be well-tolerated, with no new safety concerns identified, the filing said.</p><p>The biotechnology company's shares rose nearly 3% in afternoon trade Thursday.</p><p>Price (AUD): $0.37, Change: $+0.01, Percent Change: +2.82%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4125","symbol_name":"广播","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490828377","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490828377","pubTimestamp":1733974702,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Immutep  said its phase 2b trial evaluating eftilagimod alpha in combination with Keytruda for patients with head and neck squamous cell cancer showed \"strong\" overall survival, progression-free survival, and durability, according to a Thursday filing with the Australian bourse.The 12-month overall survival rate was 67%, well above historical controls, while the interim median duration of response was 9.3 months, the filing said. The median overall survival has not yet been reached.The Tacti-003 study also found the combination therapy continues to be well-tolerated, with no new safety concerns identified, the filing said.The biotechnology company's shares rose nearly 3% in afternoon trade Thursday.Price : $0.37, Change: $+0.01, Percent Change: +2.82%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4125":"广播","BK7508":"医药生物股","LU0426412945.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) ACC","LU0426417589.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC","BK7067":"生物科技","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","LU2238339852.HKD":"NINETY ONE GSF GLOBAL ENVIRONMENT \"A\" (HKD) ACC","IMM.AU":"IMMUTEP LTD","LU0994945656.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC 2","LU1043141123.HKD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (HKD) INC 2"},"translate_title":"Immutep表示头颈癌联合疗法的2B期试验显示出“强劲”的总体生存率；股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMM.AU":0.9,"AUD":1},"content_text":"Immutep (ASX:IMM) said its phase 2b trial evaluating eftilagimod alpha in combination with Keytruda for patients with head and neck squamous cell cancer showed \"strong\" overall survival, progression-free survival, and durability, according to a Thursday filing with the Australian bourse.The 12-month overall survival rate was 67%, well above historical controls, while the interim median duration of response was 9.3 months, the filing said. The median overall survival has not yet been reached.The Tacti-003 study also found the combination therapy continues to be well-tolerated, with no new safety concerns identified, the filing said.The biotechnology company's shares rose nearly 3% in afternoon trade Thursday.Price (AUD): $0.37, Change: $+0.01, Percent Change: +2.82%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}